Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RaC-Ad: DC Vaccine in Resected Stage IV Rare Cancers
NCT04166006Phase 2Recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Dec 2019
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dendritic cell vaccine in head and neck squamous cell carcinoma (HNSCC), Neuroendocrine Neoplasm (NEN), soft tissue sarcoma (STS), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Dec 2019; status: recruiting.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Neuroendocrine Neoplasm (NEN)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04166006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166006.